Thérapies de Conversion

Pratiques visant à modifier l'orientation sexuelle ou l'identité de genre, illégales en France depuis la loi n°2022-92, et leurs effets psychologiques documentés.

500 articles disponibles

conversion therapy
sexual orientation change effort
SOCE harm
gender identity conversion
reparative therapy mental health
ex-gay therapy
conversion practice religious

Efficacy of Pembrolizumab as Conversion Therapy in Deficient Mismatch Repair/Microsatellite Instability-High Metastatic Liver Colorectal Cancer Associated With Lynch Syndrome: A Case-Based Analysis.

Immunotherapy has emerged as a new standard of care for patients with unresectable or metastatic colorectal cancer characterized by microsatellite instability-high (MSI-H) or deficient mismatch repair…

Thérapies de Conversion
LeĂłn-SandĂ­, A. J., AgĂĽero-Moraga, J., & Ramos-Esquivel, A. (2025). Efficacy of Pembrolizumab as Conversion Therapy in Deficient Mismatch Repair/Microsatellite Instability-High Metastatic Liver Colorectal Cancer Associated With Lynch Syndrome: A Case-Based Analysis.. Cureus, 17(11), e97493. https://doi.org/10.7759/cureus.97493

Religious Minority Views on Sexual Minorities: Contemporary Ultra-Orthodox Perceptions Toward Homosexuality in Israel.

This study examined contemporary perceptions and attitudes within Israel's ultra-Orthodox (Haredi) community, a religious minority characterized by a strict interpretation of Jewish religious law, tow…

Thérapies de Conversion
Zalcberg, S., & Zalcberg-Block, S. (2025). Religious Minority Views on Sexual Minorities: Contemporary Ultra-Orthodox Perceptions Toward Homosexuality in Israel.. Arch Sex Behav, 54(10), 4259-4271. https://doi.org/10.1007/s10508-025-03316-x

A bridge over troubled waters: How can we manage patients with hepatocellular carcinoma from immunotherapy to liver transplantation?

Thérapies de Conversion
Capasso, M., Giannini, E. G., & Morisco, F. (2025). A bridge over troubled waters: How can we manage patients with hepatocellular carcinoma from immunotherapy to liver transplantation?. Dig Liver Dis, 57(11), 2065-2067. https://doi.org/10.1016/j.dld.2025.08.080

Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).

BACKGROUND & AIMS: It is unclear whether radiological complete response (rCR) and pathological complete response (pCR) after immune-based conversion therapy are associated with each other and with the…

Thérapies de Conversion
Yang, D. L., Yan, Y. H., Lai, Y. C., Wu, M. S., Dong, X. F., Chen, Y. Z., Li, W. F., Yang, F. Q., Yang, Y. Y., Zhong, T. M., Wang, G. D., Pang, Q. Q., Chen, K., Peng, N., Nong, J. L., Su, Z., Yu, Y. Q., Ye, L., Zeng, F. J., … GUIDANCE, i. n. v. e. s. t. i. g. a. t. o. r. s. (2025). Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004).. JHEP Rep, 7(11), 101587. https://doi.org/10.1016/j.jhepr.2025.101587

Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.

OBJECTIVE/BACKGROUND: The RNPLS-01 trial aimed to evaluate the efficacy and safety of ramucirumab (a VEGFR2 antagonist) combined with nab-paclitaxel, lobaplatin, and S-1 (RNPLS group) versus nab-pacli…

Thérapies de Conversion
Wang, J., Feng, F., Du, K., Yang, X., Liu, S., Xu, C., Li, M., Tan, Z., Li, X., Wang, S., Yang, X., Li, S., Yu, P., Wei, J., Xu, G., Hong, L., Zheng, J., & Yang, J. (2025). Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.. Int J Surg, 111(11), 8060-8069. https://doi.org/10.1097/JS9.0000000000002893

Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study.

BACKGROUND: Gastric cancer (GC) patients with peritoneal metastasis (PM) have a poor prognosis. Little is known about factors for successful conversion therapy in GC with PM. This study aimed to ident…

Thérapies de Conversion
Zheng, Z., & Sun, X. (2025). Predictive factors for successful conversion therapy in gastric cancer with peritoneal metastasis: a case-control study.. J Gastrointest Oncol, 16(5), 1850-1861. https://doi.org/10.21037/jgo-2025-230

Application of modified laparoscopic stomach-partitioning gastrojejunostomy for stage IV gastric cancer with gastric outlet obstruction.

Gastric outlet obstruction (GOO) is a common complication in stage IV gastric cancer, often causing malnutrition and delaying conversion therapy. Compared with conventional gastrojejunostomy (CGJ), st…

Thérapies de Conversion
Wang, H., Shao, X., Wang, P., Hu, H., Lu, Y., Jiang, Y., Li, W., Xu, Q., & Tian, Y. (2025). Application of modified laparoscopic stomach-partitioning gastrojejunostomy for stage IV gastric cancer with gastric outlet obstruction.. J Gastrointest Oncol, 16(5), 2461-2471. https://doi.org/10.21037/jgo-2025-346

Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.

INTRODUCTION: Oesophageal cancer (EC) presents a substantial global health challenge, ranking eighth in incidence and sixth in cancer-related mortality. Oesophageal squamous cell carcinoma (ESCC) is t…

Thérapies de Conversion
Wang, C., Xie, Q., Miao, Y., He, W., Wang, K., Liu, G., Fang, Q., Peng, L., Chen, Y., Zhou, J., Lv, J., Qi, Y., Wang, Q., Shi, Q., Han, Y., & Leng, X. (2025). Real-world efficacy of PD-1 inhibitors in treating oesophageal squamous cell carcinoma (ESCAPE): protocol of a multicentre, real-world, observational, cohort study.. BMJ Open, 15(10), e098524. https://doi.org/10.1136/bmjopen-2024-098524

Gaps in the "Rainbow Nation": A Critique of South Africa's Tolerance of Conversion Therapy.

South Africa has not yet enacted a specific legislative ban on conversion practices. This is despite widespread international consensus that so-called conversion practices-aimed at changing an individ…

Thérapies de Conversion
Baird, S. (2025). Gaps in the "Rainbow Nation": A Critique of South Africa's Tolerance of Conversion Therapy.. J Homosex, 1-28. https://doi.org/10.1080/00918369.2025.2573444

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.

In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. We e…

Thérapies de Conversion
Liu, Y., Xue, Q., Wang, B., Ding, X., Zhang, R., Wang, X., Ke, B., Wang, X., Liu, N., Deng, J., Zhan, H., Li, B., Wu, L., Cai, M., Zhang, L., Huang, W., Jin, P., & Liang, H. (2025). Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.. Int J Cancer, 157(8), 1637-1647. https://doi.org/10.1002/ijc.35511

Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach.

BACKGROUND: Metastatic disease traditionally classifies gastric cancer as stage M1, precluding surgical intervention and enrolling patients in palliative treatment protocols. This principle holds rega…

Thérapies de Conversion
Kyrochristou, G. D., Lianos, G. D., Kyrochristou, I. D., Mitsis, M., & Vlachos, K. (2025). Oligometastatic Gastric Cancer: Novel Considerations for Personalized Approach.. J Gastrointest Cancer, 56(1), 201. https://doi.org/10.1007/s12029-025-01325-6

Superselective transarterial chemoembolization (SSTACE) as second-line conversion therapy for locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma: a preliminary retrospective cohort study.

BACKGROUND: In patients with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma, conversion therapy has shown suboptimal efficacy, typically resulting in stable disease …

Thérapies de Conversion
Chen, J., Zhang, W., Wang, T., Fu, Y., Qing, Y., Chen, N., Ye, P., Wang, Q., Huang, H., Wei, S., & Lv, Q. (2025). Superselective transarterial chemoembolization (SSTACE) as second-line conversion therapy for locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma: a preliminary retrospective cohort study.. Eur J Med Res, 30(1), 952. https://doi.org/10.1186/s40001-025-03306-8